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Abstract 
The effects of aripiprazole, (-)-(3-hydroxyphenyl)-
N-n-propylpiperidine ((-)-3-PPP) and quinpirole on 
single and multiple pulse stimulated dopamine 
release were investigated using the technique of fast 
cyclic voltammetry (FCV) in isolated rat striatal 
slices. Aripiprazole and (-)-3-PPP had no significant 
effect on single pulse dopamine release at 
concentrations from 10nM to 10µM indicating low 
agonist activity. The compounds failed to potentiate 
5 pulse stimulated release of dopamine although 
inhibitory effects were seen at 10 µM for 
aripiprazole. Both compounds were tested against 
the concentration-response curve for quinpirole’s 
inhibition of stimulated single pulse dopamine 
release. Aripiprazole and (-)-3-PPP shifted the 
concentration-response curve for quinpirole to the 
right. In each case this was a greater than a 100-fold 
shift for the 10 µM test compound. Whilst these 
results indicate that both compounds show little 
agonist activity on dopamine release and significant 
antagonism of the inhibitory effect of quinpirole on 
dopamine release, whether they are functionally 
selective dopamine D2 ligands remains 
controversial. 
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1. INTRODUCTION 
Fast cyclic voltammetry (FCV) is a technique that 
can measure in real time the release of dopamine 
from rat striatal slices. It is therefore a useful tool to 
accurately assess the efficacy of dopamine D2 
agonists and partial agonists on stimulated single 
and multiple pulse dopamine release (Palij et al., 
1990; Bull & Sheehan, 1991; Trout and Kruk, 
1992). Full agonism may be tested on single pulse 
stimulated release, as the endogenously released 
dopamine will have no effect on the dopamine D2 
presynaptic autoreceptors. Full antagonism can be 
measured by either using a suitable multiple pulse 
protocol where endogenous dopamine D2 
autoreceptors are activated, or assessing the ability  
 
 
 
 
 
 
 
 
of the compound in question to inhibit the effect of 
a full agonist such as quinpirole on dopamine 
release (Limberger et al., 1991). 
Aripiprazole is an atypical antipsychotic and 
antidepressant used in the treatment of 
schizophrenia, bipolar disorder, and clinical 
depression.  Aripiprazole's mechanism of action is 
different from those of other FDA-approved 
atypical antipsychotics (e.g., clozapine, olanzapine, 
quetiapine, ziprasidone, and risperidone). Rather 
than antagonizing the dopamine D2 receptor, 
aripiprazole acts as a dopamine D2 and 5-HT1A 
receptor partial agonist (Ki = 0.34 nM and 1.65 nM 
respectively, Lawler et al., 1999). It can 
significantly increase dopamine levels in the 
prefrontal cortex of rats but only at low 
concentrations (Zocchi et al., 2005). 
(-)-3-PPP has also been shown to have some 
antipsychotic action but not sustained receptor 
desensitization. It has been used in schizophrenia 
possibly by attenuating dopamine function in two 
different ways, by stimulating the presynaptic 
receptors and blocking the postsynaptic receptors. It 
has previously been reported that in contrast to 
racemic 3-PPP, (+)-3-PPP can inhibit electrically 
evoked release of both [3H]dopamine and 
[14C]acetylcholine from superfused rat neostriatal 
slices (Mulder et al., 1985). In contrast (-)-3-PPP 
did not have inhibitory effects on dopamine release 
but antagonized those effects of (+)-3-PPP.  Both 
enantiomers can reduce increases in striatal 
dopamine synthesis produced by γ-butyrolactone, 
although the (-)enantiomer was only partially active 
(Clark et al., 1984). 3-PPP has also been shown not 
to protect against MPTP-induced dopaminergic 
neurotoxicity (Muralikrishnan et al., 2004). In 
contrast to the above compounds quinpirole has 
previously been shown by us and other groups to act 
as a full agonist inhibiting dopamine release in the 
rat striatum with high potency (for example see 
(Palij et al., 1990, O’Neill et al., 2009). 
The determination of the functional intrinsic activity 
of partial agonist compounds at dopamine D2 
receptors is a difficult task when carried out in brain 
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native tissues. The aim of the study was to quantify 
the potential partial agonist and antagonist activity 
of (-)-3-PPP and the dopamine D2 partial agonist, 
aripiprazole, on pre-synaptic dopamine D2 auto-
receptors located in the terminals of dopamine 
neurons in the rat striatum using FCV. We have also 
compared the effect of these compounds with that 
of the full agonist quinpirole. 
 
2. Materials and Methods 
2.1. Electrochemical System 
2.1.1. Generation of the signal 
Fast cyclic voltammetry (FCV) is an 
electrochemical technique designed to enable 
detection of monoamine release in real time (see 
Stamford, 1990 for a comprehensive review). Its 
advantages are the speed of recording and the small 
size of the working electrode (typically 7 µm 
diameter by 50 µm length). A three electrode 
configuaration is typically used in brain slice FCV, 
namely an auxiliary electrode, working electrode 
and reference electrode. The reference electrode is a 
silver/silver chloride electrode (A-M Systems, Inc, 
WA) whilst the auxiliary electrode is also a 
Ag/AgCl electrode but bridged from the bath in a 
plastic pipette tip filled with 1 M NaCl. Fast cyclic 
voltammetry (FCV) was carried out using a Millar 
Voltammeter (Dr. Julian Millar, Queen Mary & 
Westfield College, University of London, UK) 
connected to an FCV headstage (see Millar and 
Barnett, 1988 for a full circuit diagram of the 
apparatus). The FCV amplifier subjects the working 
electrode to a triphasic set of anodic and cathodic 
voltage sweeps in a period of 20 ms. The triphasic 
voltage waveform ramps from 0 to -1.0 V to +1.4 V 
to -1.0 V to 0 (20 ms) equating to a scan of 480 V/s.  
Throughout our experiments this waveform was 
applied to the potentiostat four times a second. 
Because the scan only lasts 20 ms, it can be 
repeated many times a second if required. The input 
triphasic ramp pattern for FCV in these experiments 
is shown in Fig. 1A. The FCV headstage circuit 
measures the working electrode current (generated 
by the drive voltage) and from this current the 
concentration of electrically oxidizable or 
‘electroactive’ material at the tip of the working 
electrode can be computed.  
 
2.1.2. Faradaic current 
Following the triphasic voltage input into the 
working electrode a background current is 
monitored that is due to the complex impedance 
characteristics of the electrode/ electrolyte interface 
(Fig. 1B). When electroactive materials such as 
dopamine are present on the surface of the electrode 
extra current flow is generated through the 
electrode. This electron influx is known as the 
faradaic current (Fig. 1C) and includes both 
oxidation and reduction peaks, for dopamine, 
characteristically +600 mV and -200 mV 
respectively. To provide information on dopamine 
release dynamics, a sample and hold circuit was set 
to monitor current at +600 mV on each successive 
scan. The typical output from this display in shown 
in Fig. 1D	  in response to dopamine. 
 
2.1.3. Carbon fiber electrode manufacture 
Carbon fiber electrodes were home manufactured 
but see also Armstrong James & Millar (1979). A 
borosilicate capillary tube (1 mm i.d.) was filled 
with acetone and a single carbon fiber inserted (7	  
µm	  diameter).	  Upon	  drying	  the	  tube	  the	  capillary	  was	   pulled	   by	   an	   electrode-­‐puller	   (P97,	   Sutter	  Instrument,	   Novato,	   USA)	   giving	   rise	   to	   two	  electrodes	  both	  with	  a	  glass	  seal	  around	  a	  single	  carbon	  fiber.	  The	  exposed	  length	  of	  the	  fiber	  was	  cut	  back	  mechanically	  under a microscope to give 
rise to an exposed length of approximately 50 µm. 
This enables the electrode to measure monoamines 
such as 5-hydroxtramine (O’Connor & Kruk, 1991; 
1992) and dopamine (Kruk & O’Connor, 1995) in 
very specific nuclear regions of the brain. 
2.2. Brain slice preparation 
Male Wistar rats (178-283g) housed 4 to a cage 
were purchased by NUIM fortnightly from Harlan, 
UK and kept in the BioResource Unit at NUI 
Maynooth. All experimental procedures were 
approved by the Animal Research Ethics Committee 
of the Biomedical Facility at the National Univesity 
of Ireland, Maynooth. Rats were killed by 
decapitation. The brain was quickly removed into 
ice-cold artifical cerebrospinal fluid. Blocks of 
tissue containing the caudate putamen and nucleus 
accumbens were prepared. 350 µm thick slices were 
sectioned using a Campden vibrotome. Brain slices 
were then transferred to a holding chamber 
containing artifical cerebrospinal fluid (see below) 
at room temperature (20-21oC) to equilibrate for 1 
h. A single slice was then transferred to a recording 
chamber and perfused with oxygenated aCSF at 4 
ml/min at 30-31°C for 40 min before electrical 
stimulation.  
2.3. Measurement of endogenous dopamine 
release 
Following 40 min equilibration, a bipolar tungsten-
stimulating electrode with a tip separation of 200 
µm (A-M Systems, Inc.) was placed in the 
dorsolateral caudate putamen (see Fig. 1). A carbon 
fibre electrode as described previously, was placed 
100-200 µm from the stimulating electrode. 
Stimulated dopamine release (using Neurolog 
modules) was evoked using a square-wave pulse of 
10 V amplitude and 100 µs duration delivered once 
every 2 min. A sample and hold output before 
during and after a stimulus is shown in Fig. 1D. 
Dopamine release under these conditions is 
tetrodotoxin-sensitive and Ca2+-dependent (Palij et 
al., 1990). Sample and hold data was recorded onto 
a PC via a 4 channel MacLab. Recordings were 
taken in the dorsomedial striatum (Fig. 1E). 
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2.4. Carbon fiber electrode calibration 
Electrodes were calibrated with increasing 
concentrations of freshly prepared dopamine in the 
range 0.05 µM to 1 µM, concentrations in the range 
of the endogenous dopamine released in the slices. 
The relationship of the dopamine concentration 
(µM) and the measured faradaic current (nA) was  
 
E 
 
 
Figure 1. Waveforms used in Fast Cyclic Voltammetry 
(FCV) 
A. A triphasic voltage ramp is passed down the carbon 
fibre electrode four times per second (4 Hz). The ramp 
sweeps from 0 V (relative to silver/silver chloride 
reference electrode) to -1.0 V to +1.4 V to -1.0 V and 
back to 0 V. This sweep lasts 20 ms. 
B. The resultant current measured by the carbon fibre 
electrode in called the charging current. Superimposed on 
the charging current is the current obtained when the 
electrode is placed in a ringer solution containing 1 µM 
dopamine. 
C. If the charging current in B in the absence of dopamine 
is subtracted from that current in the presence of 
dopamine a trace typical of C is the result 
(subtractogram). This is known as the faradaic current and 
is the result of the oxidation and reduction of dopamine 
on the surface of the carbon fibre electrode. Dopamine 
oxidizes at approximately +610 mV and is reduced at 
approximately -200 mV. 
D. The trace illustrated in D is the result of a sample and 
hold device measuring at +610 mV during the electrical 
stimulation of the striatum. The arrow indicates the time 
of stimulation of striatum (0.1 ms pulse width; 10 V). 
Post calibration of the CFMe indicated that approximately 
0.1µM dopamine is evoked by a single electrical 
stimulation in the dorsolateral striatum. Peak rise time is 
approximately 0.5 s and half decay time approximately 
1.0 s. 
E.  Placement of electrodes  
Schematic diagram illustrating the placement of the 
carbon fibre microelectrode (recording electrode) and the 
bipolar stimulating electrodes (tip separation 200 µm) in 
the dorsolateral striatum. The carbon fibre electrode was 
placed 100 to 200 µm from the bipolar stimulating 
electrodes most commonly in the region illustrated. 
 
found to be linear in this range (see O’Neill and 
O’Connor, 2008). 
2.5. Experimental Protocols 
Single pulse dopamine was stimulated every 2 min 
during the course of the experiment. Every 30 min a 
multiple pulse stimulation protocol was carried out 
(5 pulses at 10 Hz). Dopamine D2 antagonists have 
previously been shown to increase this signal 
(Limberger et al., 1991) but not by others (Trout 
and Kruk, 1992). Cumulative concentration 
response curves were carried out for each 
compound; 30 min baseline control, 30 min 100nM, 
30 min 1 µM and 30 min 10 µM compound. In a 
final set of experiments 2 concentrations of 
quinpirole (30 min each) were added after pre-
treatment of the brain slices for 30 min with either 
10 µM aripiprazole or -(3)-PPP. The maximum 
inhibition of dopamine release for each 
concentration of quinpirole was obtained from the 
average of the last two values during the 30 min 
perfusion. 
 
2.6. Drugs and Materials 
Artificial cerebrospinal fluid was prepared every 
day according to the following composition in mM: 
NaCl, 120; KCl, 2.5; MgSO4, 2; CaCl2, 2; 
NaH2PO4, 1.25 and D-glucose, 10 mM in H2O. It 
was bubbled with 95% O2/5% CO2. Aripiprazole 
was a gift from Dr. Paolo Cavanni, GSK, Verona. (-
)-3-PPP and quinpirole were obtained from Sigma 
(UK). Aripiprazole and (-)-3-PPP were dissolved in 
100% dimethylsulphoxide to a concentration of 10-
2M and stored at -20oC in 100µL volume containers. 
Dimethylsulphoxide final volume in aCSF was 
always <0.05%. Quinpirole was dissolved in 
artificial cerebrospinal fluid also to 10-2M. All 
compounds were used within 5 days of preparation. 
Stock solutions of dimethylsulphoxide were made 
to obtain final bath concentrations of 
dimethylsulphoxide lower than 0.005% in the 
superfusing artificial cerebrospinal fluid. Solvent 
controls were carried out with similar 
dimethylsulphoxide controls. Previous experiments 
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with 0.05% dimethylsulphoxide in the perfusing 
artificial cerebrospinal fluid did not affect single 
pulse dopamine release, rise time or decay time 
(Fig. 2; see also O’Neill & O’Connor, 2008).  
2.7. Data analysis 
All sample and hold data were analyzed and peak 
release measured. These values were exported into 
excel sheets. Single pulse evoked dopamine over 
flow was measured as the peak release in response 
to electrical stimulation. Rise time and half decay 
time of dopamine release were measured in some of 
the experiments. Rise time was measured from the 
beginning of baseline to peak amplitude and half 
decay time was measured from peak release to 50% 
half decay. Stimulated dopamine release was 
measured over 6 min (3 stimulations) prior to the 
first test drug application and the average of these 3 
values were taken as 100%. All values prior and 
subsequent to these were represented as % control. 
Quinpirole EC50 curves were generated from the 
average % inhibition (last 2 values) at the end of 
each 30 min application of quinpirole. EC50 values 
were calculated using the software package Graph 
Pad Prism. Data are presented as means±standard 
error of the mean±(S.E.M.) of at least 4 independent 
experiments (different brain slices). Students t-test 
(paired and unpaired sampling where appropriate) 
was carried out at the individual time points 
indicated in the figures.  P<0.05 was considered 
significant. 
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Figure 2. Control experiments carried out using fast 
cyclic voltammetry in slices of the rat striatum.  
A. Typical sample and hold data trace showing stimulated 
(10V, 0.1ms) dopamine release every 2 min over a 30 min 
period. The trace has been subjected to triangular 
(Bartlett) window (width 15) filtering (Chart 6.1). The 
points of stimulation are indicated by the arrows. The 
larger arrow towards the end of the trace indicates that a 
multiple pulse stimulation (5 pulses at 10 Hz) has been 
carried out. This was typically 1.5 to 1.7 times bigger than 
single pulse stimulation. Insets show on an extended time 
scale an example of a single pulse stimulated release of 
dopamine (left) and that of a 5 pulse stimulated response 
(right). 
B. Averaged time course data showing the effect of 
0.025% and 0.05% w/v DMSO on stimulated dopamine 
release. In the case of these experiments DMSO was 
applied over a 20 min time course. All subsequent 
experiments were carried out over multiples of 30 min 
time periods. The four larger points on the time course 
indicate the occurrence of the 5-pulse protocol. Peak 
dopamine release was measured from the base to 
maximum peak post stimulation using Chart Zoom and 
exported to Excel™. The average of the last 3 values prior 
to test application was taken as 100% and all values 
subsequent to these were represented as % control 
(normalized).  Data are presented as means±standard error 
of the mean (S.E.M.) of 4-7 independent experiments 
(different brain slices). 
 
 
3. RESULTS 
3.1. Control experiments 
Single pulse dopamine release was evoked every 2 
min (10V; 0.1ms duration) and was stable for more 
than 2 hr., Fig. 2A). Typically evoked single pulse 
dopamine release ranged from 0.05 to 0.12µM 
dopamine when measured against the calibrated 
electrode. Rise and decay times ranged from 0.5 to 
0.75 and 0.5 to 1 s respectively. Application of the 
solvent DMSO, used for the test compounds, at 
concentrations of 0.025 and 0.05%W/V had no 
effect on single pulse dopamine release (Fig. 2B). 5 
pulses at 10 Hz, multiple pulse stimulation, was 
evoked every 30 min and was also stable for more 
than 2 hr (Fig. 2A and B). DMSO also had no 
significant effect on multiple pulse stimulation over 
this time period. 
3.2. Effects of Aripiprazole, PPP and quinpirole 
on single and multiple pulse evoked dopamine 
release 
Application of aripiprazole and (-)-3-PPP at 
concentrations ranging from 10-8M to 10-5M each 
for 30 min, did not have any effect on single pulse 
evoked dopamine release (Fig. 3A and B 
respectively).  Aripiprazole at 10 µM but not 0.01 to 
1.0 µM significantly inhibited multiple pulse 
stimulated dopamine release (5 pulses at 10 Hz; 
paired Student t-test; **P<0.01; Fig. 3A).  Fig. 3C 
illustrates the inhibitory effect of quinpirole on 
single pulse dopamine release. Increasing 
concentrations of quinpirole (10 nM to 100 nM) 
were added to the brain slice chamber and complete 
inhibition of dopamine release occurred at 100 nM. 
An EC50 value of 32nM was calculated for 
quinpirole from the software package Graph Pad 
Prism. This is in agreement with other 
publications using this technique (see O’Neill et al., 
2009). 
3.3. Effects of Aripiprazole and PPP on the 
inhibition of dopamine release by quinpirole 
Two concentrations of quinpirole (1 and 10 µM) 
were applied for 30 min to brain slices, which, had 
been pretreated with 10 µM of either aripiprazole or 
(-)-3-PPP. Fig. 4A and B shows the averaged time 
course data showing the effect of 1.0 and 10 µM 
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quinpirole on stimulated dopamine release in the 
presence of 10 µM aripiprazole (A) or (-)-3-PPP 
(B). EC50 values for quinpirole alone and in the 
presence of aripiprazole (10µM) were 38 nM and 
7.4 µM respectively. This represents a 200 fold 
right-ward shift in the concentration response curve.  
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Figure 3. The effect of aripiprazole, 3-PPP and quinpirole 
on stimulated dopamine release in brain slices of the rat 
striatum.  
A. Averaged time course data showing the effect of 0.01, 
0.1, 1.0 and 10 µM aripiprazole on stimulated dopamine 
release. The upper four points represent the 5-pulse 
protocol every 30 min. Aripiprazole did not have any 
effect on single pulse release at any of the concentrations. 
However 5 pulses at 10Hz was significantly inhibited at 
10 µΜ only (paired Student t-test; *P<0.01; n=4).  
B. Averaged time course data showing the effect of 0.01, 
0.1, 1.0 and 10 µM 3-PPP on stimulated dopamine 
release. The upper six points represent the 5-pulse 
protocol every 30 min. 3-PPP did not have any effect on 
single or multiple pulse release at any of the 
concentrations tested.  
C. Averaged time course data showing the effect of 10 
and 100 nM quinpirole on single pulse stimulated 
dopamine release. Quinpirole had a potent inhibitory 
effect on dopamine release with 10 nM and 100 nM 
inhibiting release by 25 and 85% respectively as 
previously reported. 
 
In the presence of (-)-3-PPP the EC50 values were 
38 nM and 5.6 µM (a 150 fold shift; Fig. 4C and D 
respectively).  
 
 
4. DISCUSSION 
Using the technique of fast cyclic voltammetry it 
was expected that the agonist activity of dopamine 
compounds would manifest in an inhibition of 
single pulse stimulated dopamine release. On the 
other hand if a multiple pulse protocol was used to 
stimulate dopamine release and thus activate 
dopamine D2 autoreceptors, it might be expected 
that the antagonist activity of a test compound 
might increase stimulated dopamine release.  Using 
FCV we also investigated if a partial antagonist 
applied at low concentrations might give rise to 
agonist activity alone whilst show antagonist 
activity at higher concentrations. 
 Surprisingly application of the standard dopamine 
D2 partial agonist aripiprazole had no significant 
effect on single pulse release at concentrations from 
10 nM to 10 µM. Aripiprazole is known to be very 
active at dopamine D2 receptors (pEC50/pKi ~ 
9.5/9.8) and a starting concentration of 10 nM is 
greater than 10 fold higher than its pEC50 (Lawler et 
al., 1999). Therefore lower concentrations of this 
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Figure 4. Effect of aripiprazole and 3-PPP in the presence 
of the dopamine D2 receptor agonist quinpirole on 
dopamine release.  
A. Averaged time course data showing the effect of 1 µM 
and 10 µM quinpirole (indicated by black line bars) on 
stimulated dopamine release in the presence of 10 µM 
aripiprazole (present throughout the experiment).  
B. Averaged time course data showing the effect of 1 µM 
and 10 µM quinpirole (indicated by black line bars) on 
stimulated dopamine release in the presence of 10 µM 3-
PPP (present throughout the experiment). All data in A 
and B is presented as means±standard error of the mean 
(S.E.M.) of 4-5 independent experiments (different brain 
slices). 
C. EC50 curves for the effect of quinpirole alone (0.01 and 
0.1 µM; black squares, left) and quinpirole in the presence 
of aripiprazole (10 µM, open circles; right) on single 
pulse dopamine release. IC50 values were estimated using 
the software package Graph Pad Prism. There is an 
approximate 200-fold shift to the right of the curve in the 
presence of 10 µM aripiprazole (see results section for 
values).  
D.  EC50 curves for the effect of quinpirole alone (0.01 
and 0.1 µM; black squares, left) and quinpirole in the 
presence of 3-PPP (10 µM, triangles; right) on single 
pulse dopamine release. There is an approximate 150-fold 
shift to the right of the curve in the presence of 10 µM 
aripiprazole. In both C and D results are expressed as 
percentage inhibition of dopamine release against log 
molar concentration of quinpirole. All data is presented as 
the mean of 4 to 7 independent experiments (different 
brain slices). 
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partial agonist may be required to be tested 
(typically <1nM) to see an agonist effect. Therefore 
from these data alone we cannot determine if 
aripiprazole is a typical dopamine D2 agonist or a 
functionally selective dopamine D2 ligand. Another 
reason higher concentrations did not give rise to an 
inhibition of dopamine release may be that other 
receptors can be consistently occupied at that 
concentration (10 to 100 nM). For example 
aripiprazole at this concentration may have small 
but significant effects on dopamine D2, D3, D4, 
5HT1A/2A/2B/2C/7, alpha1A/1B and H1 receptors (Jordan 
et al., 2002). It is not known at this time if all of 
these receptors can directly or indirectly influence 
dopamine release. However in the region we are 
recording from it is unlikely that activation of all of 
these receptors plays a major role in the modulation 
of presynaptic dopamine release. Experiments using 
(-)-3-PPP (another known partial agonist) also did 
not detect inhibitory effects on single pulse 
dopamine release at 10 nM, 100 nM and 1 µM. 
For both compounds the 5-pulse protocol, which 
was used to look at antagonist activity, did not show 
any significant increases in dopamine release in the 
presence of all four concentrations. This may be that 
the protocol is not suitable to observe these effects 
(see Limberger et al., 1991 and in contrast, Trout 
and Kruk, 1992). Longer stimulation protocols such 
as 10 or 20 pulses at 10 to 100 Hz would have 
detrimental effects on the concurrent single pulse 
experiments and these would have to be separated 
out. Therefore this protocol may not be as useful as 
an assessment of antagonist activity.  Because of 
this it was decided to test the antagonist effects of 
the compounds on the inhibition of dopamine 
release by quinpirole. 
Both compounds when present at 10 µM caused an 
approximate 150 to 200-fold shift to the right of the 
quinpirole concentration-response curve which 
compares favorably with the actions of other full 
antagonists at dopamine D2 receptors in previous 
work using this technique (Palij et. al., 1990; Bull 
and Sheehan, 1991 in both the rat striatum and 
nucleus accumbens). Our results were similar to the 
antagonistic effects of sulpiride, metoclopramide 
and clozapine. 
The fact that aripiprazole can modulate in vivo 5-
HT and DA release in mPFC through the activation 
of 5-HT1A receptors may be a concern (Bortolozzi et 
al., 2007).  These effects of aripiprazole in the 
cortex were through partial agonist activity at 
dopamine D2 autoreceptors and distinct from those 
of haloperidol.  In a recent study a role for 
aripiprazole has been uncovered at dopamine D3 
autoreceptors also (Tadori et al., 2008). We did not 
investigate its actions at these receptors in this 
study. The new generation antipsychotics including 
aripiprazole all seem to preferentially increase 
dopamine output in the nucleus accumbens as 
compared to the striatum (Hertel, 2006). It would be 
interesting to look at the effects of these agents in 
the nucleus accumbens. Partial agonist properties of 
aripiprazole were not revealed in studies carried out 
by Koener et al., (2011) using guanosine 5′-O-(γ-
[³⁵S]thiotriphosphate ([³⁵S]GTPγS) binding assays 
on striatal membranes from haloperidol-treated rats. 
This was also observed in behavioral assays. In fact 
aripiprazole behaved as an antagonist, efficiently 
inhibiting the functional response to dopamine. 
In a micro-dialysis study by Oshibuchi et al., 
(2009), both aripiprazole and the full antagonist 
haloperidol equally suppressed increases in 
dopamine levels in fear conditioned rats. However 
only aripiprazole decreased tonic dopamine levels. 
This may indicate a differential effect of 
aripiprazole on tonic and phasic dopamine release.  
Whether aripiprazole is a typical dopamine D2 
partial agonist, or a functionally selective dopamine 
D2 ligand, remains controversial (Urban et al., 
2007).  These authors have shown downstream 
signaling differences between aripiprazole and both 
quinpirole and (-)-3-PPP. Using G protein activation 
and prolactin release as a measure of dopamine D2 
receptor activation, Cosi et al., (2006) showed that 
aripiprazole acted as a partial agonist at dopamine 
D2 receptors. It is also likely that sensitivity to 
aripiprazole is different between humans and 
rodents. In an interesting computer simulation 
report by Spiros et al., (2010), aripiprazole was 
tested at dopamine D2 receptors and predicted to 
have greater dopamine D2 receptor antagonism in 
the human than in the rodent. 
Our results also indicate competitive antagonism for 
the effects of (-)-3-PPP on the inhibition of 
dopamine release by quinpirole. Early reports on the 
activity of (-)-3-PPP at dopamine D2 receptors are 
also equivocal. Plantje et al. (1983; 1984), similar to 
our data, were able to demonstrate an antagonist 
effect of (-)-3-PPP in the rat striatum investigating 
the inhibition of K+-induced [3H]acetylcholine 
release caused by the dopamine D2 receptor agonist 
LY 141865. In the same year Markstein and Lahaye 
(1983) observed contrasting results where (-)-3-PPP 
did not inhibit electrically-evoked tritium overflow 
from rat striatal slices pre-incubated with 
[3H]dopamine. Arbilla and Langer (1984) 
investigated the action of both enantiomers of 3-
PPP on spontaneous and electrically evoked 3H 
dopamine release in the striatum of rabbits. (+)-3-
PPP increased spontaneous dopamine overflow but 
inhibited electrically evoked dopamine release. In 
contrast to (+)-3-PPP,  (-)-3-PPP increased 
electrically evoked dopamine release with no effect 
on spontaneous overflow. Furthermore similar to 
the findings presented here, (-)-3-PPP antagonized 
the inhibitory effect of apomorphine, d-
amphetamine and (+)-3-PPP on evoked dopamine 
release. Finally Stamford et al., (1991) working in 
vivo and using a longer stimulation protocol 
observed increases in dopamine release in the 
striatum and nucleus accumbens in the presence of  
(-)-3-PPP.  The (+) enantiomer presumable acting as 
a full agonist caused a decrease in release in the 
nucleus accumbens and little effect in the striatum. 
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5. Conclusion 
To date there has been equivocal data on the actions 
of both aripiprazole and (-)-3-PPP as partial 
agonists at dopamine D2 presynaptic autoreceptors. 
Our results indicate that whilst both compounds 
show little agonist activity on single pulse dopamine 
release at low and high concentrations, they have 
significant antagonistic properties at dopamine D2 
auto-receptors. 
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